Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer CEO Ian Read provided Wall Street with more clarity on his vision for the company as it moves beyond Lipitor into a new era. Pfizer will have two primary businesses, he said, an innovative pharmaceutical engine and a value business.

Advertisement

Related Content

“The Pink Sheet” DAILY – Most Notable Stories Of 2012
Pfizer Downplays Risk Of Tofacitinib Panel Review As It Pushes Focus On Innovation
Pfizer Head of Preclinical Outsourcing VP Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships: An Interview With PharmAsia News (Part 1 of 2)
Pfizer’s Richard Connell On “Pausing” Anti-Infectives Research In China, And Taking A Long View On Asian Partnerships
On Building A Better R&D Machine, Part 1: Pfizer’s R&D Chief Mikael Dolsten Talks Organizational Structure And Innovation
Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)
Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile
Lipitor Watch: Pfizer Hangs On To Share, But At What Cost?
Tofacitinib Data Is In: As Effective As Humira, But Safety Remains A Question
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out

Topics

Advertisement
UsernamePublicRestriction

Register

PS073328

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel